Behind the Paper
The real stories behind the latest research papers, from conception to publication, the highs and the lows
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150
Proton pump inhibitors (PPIs) are commonly used concomitant to cancer treatment and they induce gut microbiota changes. It’s increasingly apparent that gut dysbiosis can reduce the effectiveness of immune checkpoint inhibitors (ICI). However, little is known on PPI effects on outcomes with ICIs.
When your body attacks itself – BTK inhibition shows promise for the treatment of chronic spontaneous urticaria (an autoimmune disease)
In a recent clinical trial, patients who had chronic spontaneous urticaria (CSU) for more than 6 months that would not respond to high doses of standard treatment (H1-antihistamines) – were enrolled to evaluate a “BTK blocker” drug, called, "fenebrutinib".
Silver nanoparticle-incorporated hydrogel augments the cancer immunotherapy through modulating oral microbiome
Hydrogel-embedded silver nanoparticles and specific exogenous bacteria augment anti-tumour immune responses of oral squamous cell carcinoma by modulation of oral microbiota.
EGF-SNX3-EGFR axis drives tumor progression and metastasis in triple-negative breast cancers
Sorting Nexin 3 (SNX3), a member of the recycling retromer complex, is a critical player in the epidermal growth factor (EGF) stimulated EGFR network in triple-negative breast cancers.
A negative NKX2-1/DUSP6/ERK signal inhibits lung cancer
Lung cancer is the #1 cancer killer in the U.S. Lung cancer’s heterogenous pathology and complicated oncogenic signaling networks have impeded care.
Higher Bleeding Rates Found with Direct Oral Anticoagulants in Myeloproliferative Neoplasm Patients
In this study we evaluated thrombosis and bleeding outcomes in myeloproliferative neoplasm (MPN) patients treated with direct oral anticoagulants (DOACs). We found an unexpected high cumulative incidence of bleeding, emphasizing the need for continued rigorous evaluation of DOACs in MPNs.
